A Multi-Source Investigation of Issues Arising from the Implementation and Evolution of a Commercial, Non-Medical Cannabis Mark
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cannabis in New Zealand Perceptions of Use, Users and Policy
Cannabis in New Zealand perceptions of use, users and policy Geoff Noller A thesis submitted for the degree of Doctor of Philosophy at the University of Otago, Christchurch Aotearoa, New Zealand November 5, 2008 ABSTRACT Introduction Despite humanity’s lengthy relationship with psychoactive substances, their consumption in contemporary societies is perceived as highly problematic. Cannabis, the most commonly imbibed illicit psychotropic, has come to embody these concerns. Medical and scientific research informs notions of use and user, with these being further constructed in the public realm by law, the media and policy against a backdrop of health deficits and other harms including risk taking, criminality and deviance. With many studies drawing on clinical populations, e.g. high intensity users or those in treatment, a pathologized view of the user predominates. Where general population studies incorporate user data, these typically concentrate on the epidemiology of use: frequency, intensity, duration, and symptoms of abuse and dependence. This, however, tells us little about the meaning of use for users or why use continues despite universal official disapprobation. A lack of studies incorporating user perspectives thus ensures the limited focus of much present research and a policy accent on supply reduction at the expense of harm minimisation and safe use education. Those choosing to continue use are stigmatised as deviant or dependant. This has the effect of further bolstering enforcement, a strategy showing little evidence of efficacy. The present study sought a comparison between this dominant discourse on cannabis use and the perspectives of users, with a range of exploratory hypotheses being identified. Method Eighty cannabis-using respondents participated in open-ended face-to-face interviews, of which seventy-six successfully completed a follow-up questionnaire. -
11-05-18 DRAFT 4:41 PM UTAH MEDICAL CANNABIS ACT 1 2018 THIRD SPECIAL SESSION 2 STATE of UTAH 3 4 LONG TITLE 5 General Descript
11-05-18 DRAFT 4:41 PM 1 UTAH MEDICAL CANNABIS ACT 2 2018 THIRD SPECIAL SESSION 3 STATE OF UTAH 4 5 LONG TITLE 6 General Description: 7 This bill provides for the cultivation, processing, medical recommendation, and patient use of 8 medical cannabis. 9 Highlighted Provisions: 10 This bill: 11 ▸ defines terms; 12 ▸ provides for licensing and regulation of a cannabis cultivation facility, a 13 cannabis processing facility, an independent cannabis testing laboratory, and a 14 medical cannabis pharmacy; 15 ▸ provides for security and tracking of medical cannabis and a medical cannabis 16 product from cultivation to consumptionuse to ensure safety and chemical content; 17 ▸ requires certain labeling and childproof packaging of medical cannabis and a 18 medical cannabis product; 19 ▸ requires the Department of Agriculture and Food, the Department of Health, the 20 Department of Public Safety, and the Department of Technology Services to create 21 an electronic verification system to facilitate recommendation, dispensing, and 22 record-keeping for medical cannabis transactions; 23 ▸ allows an individual with a qualifying condition to obtain a medical cannabis 24 patient card on the recommendation of a certain medical professional to gain access 25 to medical cannabis; 26 ▸ allows a patient to designate a caregiver to assist with accessing medical 27 cannabis; 28 ▸ provides thatfor a parent or legal guardian isto obtain a medical cannabis 29 guardian card for an eligible minor patient and for the designated caregiver for a 30 minorminor patient -
Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16. -
Effective 12/3/2018 Superseded 3/26/2019 4-41A-701 Cannabis and Cannabis Product Testing. (1) a Medical Cannabis Pharmacy and Th
Utah Code Effective 12/3/2018 Superseded 3/26/2019 4-41a-701 Cannabis and cannabis product testing. (1) A medical cannabis pharmacy and the state central fill medical cannabis pharmacy may not offer any cannabis or cannabis product for sale unless an independent cannabis testing laboratory has tested a representative sample of the cannabis or cannabis product to determine: (a) (i) the amount of total composite tetrahydrocannabinol and cannabidiol in the cannabis or cannabis product; and (ii) the amount of any other cannabinoid in the cannabis or cannabis product that the label claims the cannabis or cannabis product contains; (b) that the presence of contaminants, including mold, fungus, pesticides, microbial contaminants, heavy metals, or foreign material, does not exceed an amount that is safe for human consumption; and (c) for a cannabis product that is manufactured using a process that involves extraction using hydrocarbons, that the cannabis product does not contain a level of a residual solvent that is not safe for human consumption. (2) By rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the department: (a) may determine the amount of any substance described in Subsections (1)(b) and (c) that is safe for human consumption; and (b) shall establish protocols for a recall of cannabis or a cannabis product by a cannabis production establishment. (3) The department may require testing for a toxin if: (a) the department receives information indicating the potential presence of a toxin; or (b) the department's inspector has reason to believe a toxin may be present based on the inspection of a facility. -
FDA Office of Women's Health US Food and Drug Administration
FDA OFFICE OF WOMEN’S HEALTH SCIENTIFIC CONFERENCE CBD & Other Cannabinoids Sex and Gender Differences in Use and Responses Thursday, November 19, 2020 | 9:00 AM–4:00 PM EST Virtual Meeting CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses | 1 !/"'""'', 11 U.S. FOOD & DRUG •J ADMINISTRATION Dear Colleagues, On behalf of the U.S. Food and Drug Administration's (FDA) Office of Women's Health (OWH), I am pleased to welcome you to today's conference, "CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses." The mission of FDA is to protect and promote public health. A top priority for OWH is to identify and monitor emerging areas of interest and potential concern for the health of women. Cannabidiol (CBD) products are appearing everywhere - from medical cannabis dispensaries, to pharmacies, to gas stations. Many of these products are illegally marketed and purport to target a myriad of health concerns, including conditions more commonly experienced by women than men, such as chronic pain, sleep disturbances, anxiety and depression. Given that little is known about how and if many cannabis derived products work, how and why women are using them, and their potential associated risks, there is a mounting need to consolidate and communicate what we know about these products and to identify knowledge gaps. Further, the use of these products during pregnancy and lactation raises additional questions and concerns. The purpose of today's meeting is to highlight the needed and existing research to address the many "who", "what", and "why" questions surrounding products containing CBD and other cannabinoids. -
Overview of the WSLCB Rule Development Process Sara Cooley Broschart
Overview of the WSLCB Rule Development Process Kathy Hoffman, MPA, MALC Policy and Rules Manager Washington State Liquor and Cannabis Board Prevention Summit November 4, 2020 Presentation Outline Today’s Presentation • WSLCB rule development process, including: • What does the WSLCB do? • Rule development process • From concept to completion • How to get involved • Statutory and regulatory authority • The most effective ways to provide input and comment • Current Rule Projects and Future Rule Projects Presentation Outline Who is WSLCB and what does WSLCB do? • Three-person Board • License liquor, cannabis, vapor and tobacco product production, processing and product sale. Presentation Outline Rule Development Process Basic Rule Making Process The standard rule making process is described in chapter 34.05 RCW, the Administrative Procedures Act, and divided into three stages: • Stage 1: Pre-proposal Statement of Inquiry (CR-101) – RCW 34.05.310 • Stage 2: Proposed Rule Making (CR-102) - RCW 34.05.320 • State 3: Rule-making Order (CR-103) - RCW 34.05.360 Each stage consists of specific tasks and processes. Start CR-101 Pre-proposal . Statement of Inquiry CR-102 Proposal Public Hearing: Oral Testimony Written Testimony Stakeholder Engagement: Listen and Learn Forums Draft Conceptual Rule Workshops DeliBerative Dialogue Sessions CR-103 Final Agency Responds Adoption to Comments Rule development, drafting, Finish and analysis Standard Rule Making – Stage 1 Pre-Proposal Statement of Inquiry (CR-101) – RCW 34.05.310 Purpose: Describes the issue(s) being considered for rule development • The CR-101 identifies the purpose and scope of rulemaking. • The scope of the rules created through this process is controlled by statutory authority and must be compatible with existing requirements. -
TY18:Layout 1 17/08/09 16:06 Pagina 1 TY18:Layout 1 17/08/09 16:06 Pagina 2 TY18:Layout 1 17/08/09 16:06 Pagina 3 TY18:Layout 1 17/08/09 16:06 Pagina 4
TY18:Layout 1 17/08/09 16:06 Pagina 1 TY18:Layout 1 17/08/09 16:06 Pagina 2 TY18:Layout 1 17/08/09 16:06 Pagina 3 TY18:Layout 1 17/08/09 16:06 Pagina 4 Publisher/ Editor in Chief Marco Renda [email protected] Assistant to Editor Jef Tek [email protected] Copy Editor Aendrew Rininsland [email protected] Magazine design & layout Ivan Art [email protected] Director of Sales & Marketing Michelle Rainey [email protected] Technical Writer Ally a.k.a Pflover [email protected] Q&A Advisor Shantibaba [email protected] Text & photography Contributors Marco Renda, Ændrew Rininsland, Ivan Art, Michelle Rainey, Otto Snow, PFlover, Jef Tek, Shantibaba, Jerry B., Soma, Jay Generation, Harry Resin, Dr Dog, Chris Thompson, Jeremy Norrie, Keith Fagin, John (Shiva), Lara Lesack, Richard Owl Mirror, Suggarpaw, British Hempire, Jackie Sutton, Salvatore Messina HD., David B. Allen M.D., Hashmasta-Kut, Ale Keppel, Gregorio “Goyo” Fernandez Cover Pic `Mr Nice Critical Mass flower at 6 weeks` by Gregorio Fernandez “Goyo” for Mr. Nice Seedbank Submissions [email protected] Treating Yourself 250 The East Mall, P.O. Box 36531 Etobicoke, Ontario M9B 3Y8 Canada T: + 416 620 1951 F: +416 620 0698 Printed in Canada 4 - Treating Yourself, Issue 18- 2009 TY18:Layout 1 17/08/09 16:06 Pagina 5 Marco’s Editorial Well I have to say issue number 17 certainly caused a lot of controversy, especially surrounding the Dr Frankenbeanstien article. Both Sam The Skunkman and Ed Rosenthal contacted me regarding this. I offered them both the chance to rebut what was published, but they declined to do so. -
Effects of Combined THC and Heroin Vapor Inhalation
Psychopharmacology https://doi.org/10.1007/s00213-021-05904-w ORIGINAL INVESTIGATION Efects of combined THC and heroin vapor inhalation in rats Arnold Gutierrez1,2 · Jacques D. Nguyen1,2 · Kevin M. Creehan1,2 · Mehrak Javadi‑Paydar1 · Yanabel Grant1,2 · Michael A. Tafe1,2 Received: 27 April 2021 / Accepted: 27 May 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 Abstract Rationale Opioids are efective medications, but they have several key limitations including the development of tolerance, establishment of dependence, diversion for non-medical use, and the development of addiction. Therefore, any drugs which act in an additive or synergistic fashion with opioids to address medical applications have the potential to reduce opioid- related harms. Objectives To determine if heroin and Δ9-tetrahydrocannabinol (THC) interact in an additive or independent manner to alter nociception, body temperature, and spontaneous locomotor activity when inhaled or injected. Methods Groups of female and male rats, implanted with radiotelemetry transmitters, were exposed to vapor generated from heroin (50 mg/mL in propylene glycol vehicle; PG), THC (50 mg/mL), or the combination for assessment of efects on temperature and activity. Thermal nociception was assessed with a warm water tail-withdrawal assay. Results Heroin inhalation increased temperature and activity whereas THC inhalation decreased temperature and activity in both female and male Sprague–Dawley rats. Efects of combined inhalation were in opposition, and additional experiments found the same outcome for the injection of heroin (0.5 mg/kg, s.c.) and THC (10 mg/kg, i.p.) alone and in combination. -
Openvape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents
Research Article: Open Source Tools and Methods | Novel Tools and Methods OpenVape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents https://doi.org/10.1523/ENEURO.0279-20.2020 Cite as: eNeuro 2020; 10.1523/ENEURO.0279-20.2020 Received: 27 June 2020 Revised: 30 July 2020 Accepted: 18 August 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 Frie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 Manuscript Title Page Instructions 2 1. Manuscript Title (50 word maximum) 3 4 OpenVape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents 5 2. Abbreviated Title (50 character maximum) 6 7 OpenVape: an Open-Source Vapour Exposure Device 8 3. List all Author Names and Affiliations in order as they would appear in the published article 9 10 Jude A. Frie – Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 11 Ontario, Canada. 12 Jacob Underhill – Department of Biomedical Sciences, Ontario Veterinary College, University of 13 Guelph, Ontario, Canada. 14 Bin Zhao – Departments of Pharmacology and Toxicology, University of Toronto, Ontario, Canada 15 Giordano de Guglielmo – Department of Psychiatry, University of California, San Diego, San Diego, 16 California, USA. -
How Adam Bierman Built Medmen Into an Influential Industry Player
Creating a best-selling cannabis edible in a crowded market $12.95 VOL 4 • ISSUE 8 • September 2017 Crop storage+ strategies Vape industry overview Getting a grow NO off the ground APOLOGHow Adam Bierman built ¬ES MedMen into an influential industry player despite his blunt, controversial style 312.869.9070 IF YOU’RE NOT MESSAGING YOUR CUSTOMERS, THEN SOMEBODY ELSE IS! SMS is the best and most effective way to increase your daily store traffi c. Our clients say a blast brings in 10-50 incremental customers (per 1000 messaged). MESSAGING PAYS FOR ITSELF 10 TIMES OVER! A 420 sending number to increase Reliable delivery. No blocking. brand effectiveness. Excellent customer service. UP TO 240 CHARACTERS PER MESSAGE Need help building your opt in list? (50% more than others). More info to We got you covered. your customers means more sales. Great prices. Discounts for Picture messaging (MMS) available. higher volumes. No contracts or setup fees. 90% OF SMS ARE READ WITHIN 3 MINUTES OF RECEIPT. 4 20 YOU CAN’T AFFORD Thursday, April 20 NOT TO USE NORTHTEXT. Dispensary now SMS messaging expertise tailored specifi cally to the Dispensary market WWW.NORTHTEXT.COM/DISPENSARY | 312.869.9070 In business since 2007 Trim-8.375x10.875.qxp_Layout 1 1/20/17 10:22 AM Page 1 System 420™ Hybrid Greenhouses Larger Yields, Better Crops, Lower Costs PRODUCTION YIELDS With over 1 million square feet of Light deprivation, environmental controls, and benching systems Why Nexus? cannabis greenhouses constructed in provide the tools to optimize the 11 states, Nexus has developed unique expertise in designing grow system for high capacity integrated cannabis growing systems. -
Manifiesto Internacional OMS Cannabis Traducido 1:12
Naciones Unidas E/CN.7/2020/NGO/7 Distr.: General Consejo Ecónomico y Social 25 November 2020 English only Comisión en drogas narcóticas Reanudada la sexagésimo tercera sesión Vienna, 2–4 diciembre 2020 Item 5 de la agenda provisional* Implementación de tratados de control de drogas internacionales Declaración presentada por la coalición europea por la justicia y políticas de drogas eficaces, una organización no gubernamental reconocida como entidad consultiva por el Consejo Social y Económico El Secretario-General ha recibido el siguiente manifiesto, el cual está siendo circulado de acuardo a los párrafos 36 y 37 de la resolución 1996/31 del Consejo Económico y Social __________________ * E/CN.7/2020/1/Add.1. ** Issued without formal editing. V.20-06992 (E) 261120 291120 *2006992* E/CN.7/2020/NGO/7 Manifiesto Apoya el acceso de pacientes a su medicina, ¡vota que sí! La cannabis ha sido una medicina convencional desde el amanecer de la civilización. En 1902 y 1929 las medicinas cannábicas fueron discutidas en la Conferencia Internacional por la Unificación de las Fórmulas Farmacopeicas para Drogas Potentes, la cual proporcionó pautas para armonizar las medicinas de cannabis y proveer a pacientes de drogas seguras y estandarizadas para sus tratamientos. Para este tiempo la cannabis ya era bastante aceptada en la práctica clínica y había sido reportada en las Farmacopeas de Austria, Bélgica, Francia, Hungaria, Italia, Japón, Holanda, Suiza, Reino Unido, Estados Unidos de América, así como en México y España. En 1958, las Naciones Unidas reportaron que la cannabis estaba también en las Farmacopeas de Argentina, Brazil, China, Egypt, Finland, India, Portugal, Romania, la URSS, y Venezuela.(2) Muchas preparacionas cannábicas están en textos ancestrales que componen la Farmacopea Ayurvédica (Charaka Samhita, Sushruta Samhita, Shargandhara Samhita) y en las Farmacopeas Mediterráneas de Umdat at-tabîb, Jami' al-mufradat, Hadîqat al-azhâr or Tuhfat al-ahbâb. -
New Zealanders Experiences of Cannabis in Amsterdam While on Their Overseas Experience (OE)
Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. i Flight of the Kiwi New Zealanders experiences of Cannabis in Amsterdam while on their Overseas Experience (OE) A thesis presented in partial fulfilment of the requirements for the Degree of Masters in Health Psychology At Massey University Manawatu New Zealand. Gabrielle Margaret Colley 2019 ii Abstract Cannabis consumption and travelling share a number of similarities, such as evoking pleasure or anxiety and, like in the title used to reflect this thesis, represent the experience of “flight” for the “Kiwi” (New Zealander). This thesis therefore explores both the experiences of cannabis consumption, a flight of the mind and travelling a flight of the body. The aim was to understand how New Zealanders experience cannabis in Amsterdam while they are undertaking a working holiday based in the United Kingdom (UK), known within Aotearoa New Zealand as an Overseas Experience (OE). Given Aotearoa New Zealand’s current political debates on cannabis control and the upcoming 2020 public referendum on legalising the substance, this thesis provides an opportunity to explore how New Zealanders experience cannabis within a liberal country that tolerates the sale of soft drugs in licensed premises, while growing up in a country that enforces cannabis prohibition. Statistics on cannabis use illustrate a steady rise in global consumption, however majority of countries still implement prohibition as a method of control, therefore choosing to study New Zealanders use of cannabis in a country without any legal ramification or stigmatisation for personal consumption allowed for greater transparency and in depth exploration.